In our extended in vitro study [44], we accordingly observed that exogenous IL-2 at a physiologic dose of 500 IU/mL was able to correct Treg numbers and function compromised only in progressive RA patients with a baseline IL-2 systemic deficit, which confirms the strong dependence of Tregs on IL-2 availability. The gene discussed is IL2; the disease is rheumatoid arthritis.